Kidney Cancer Stages

Staging tells your doctor how far the cancer has grown inside or beyond the kidney, whether nearby lymph nodes are involved, and whether disease has spread to distant organs. For kidney cancer, the most widely used system is the American Joint Committee on Cancer Tumour-Node-Metastasis classification, 8th edition (AJCC TNM 8e), adopted at every major centre across the National Capital Region [^1]. The staging combines three pieces of information. T describes the size of the primary tumour and whether it stays within the kidney capsule or pushes into surrounding fat, the renal vein, the inferior vena cava, or structures beyond Gerota fascia. N records whether regional lymph nodes contain cancer. M records whether there is spread to a distant site such as lung, bone, liver or brain [^2].

Doctors assign a clinical stage before surgery using cross-sectional imaging and assign a pathological stage after the kidney specimen is examined under the microscope. The pathological stage is more precise because the pathologist can measure exact tumour dimensions, assess margins and look for microscopic vein invasion that imaging sometimes misses.

A second layer of prognostication exists for advanced disease. When kidney cancer has spread, medical oncologists use the International Metastatic Renal Cell Carcinoma Database Consortium model, often called the IMDC or Heng criteria, to separate patients into favourable, intermediate and poor risk groups. This risk group, rather than the TNM stage alone, drives the choice between immunotherapy combinations and targeted therapy in the first line setting. For localised disease removed by surgery, tools such as the SSIGN score and the Leibovich model estimate the likelihood of recurrence using pathological features including stage, size, grade, necrosis and sarcomatoid differentiation.

Understanding the stage helps patients and families in Delhi, Gurgaon and Noida ask the right questions at the tumour board and plan the practical side of care, from whether a partial nephrectomy is possible to whether systemic therapy will be needed afterward.

Staging tells your doctor how far the cancer has grown inside or beyond the kidney, whether nearby lymph nodes are involved, and whether disease has spread to distant organs. For kidney cancer, the most widely used system is the American Joint Committee on Cancer Tumour-Node-Metastasis classification, 8th edition (AJCC TNM 8e), adopted at every major centre across the National Capital Region [^1] [^2]. The staging combines three pieces of information. T describes the size of the primary tumour and whether it stays within the kidney capsule or pushes into surrounding fat, the renal vein, the inferior vena cava, or structures beyond Gerota fascia. N records whether regional lymph nodes contain cancer. M records whether there is spread to a distant site such as lung, bone, liver or brain.

Doctors assign a clinical stage before surgery using cross-sectional imaging and assign a pathological stage after the kidney specimen is examined under the microscope. The pathological stage is more precise because the pathologist can measure exact tumour dimensions, assess margins and look for microscopic vein invasion that imaging sometimes misses.

A second layer of prognostication exists for advanced disease. When kidney cancer has spread, medical oncologists use the International Metastatic Renal Cell Carcinoma Database Consortium model, often called the IMDC or Heng criteria, to separate patients into favourable, intermediate and poor risk groups. This risk group, rather than the TNM stage alone, drives the choice between immunotherapy combinations and targeted therapy in the first line setting. For localised disease removed by surgery, tools such as the SSIGN score and the Leibovich model estimate the likelihood of recurrence using pathological features including stage, size, grade, necrosis and sarcomatoid differentiation.

Understanding the stage helps patients and families in Delhi, Gurgaon and Noida ask the right questions at the tumour board and plan the practical side of care, from whether a partial nephrectomy is possible to whether systemic therapy will be needed afterward.

The TNM system provides the anatomical foundation for staging kidney cancer at diagnosis. T describes the extent of the primary tumour, N the regional lymph node status, and M the presence of distant metastases. This straightforward classification allows clinicians to communicate with precision and compare outcomes between institutions [^2].

For patients with metastatic disease, TNM staging alone is insufficient to predict treatment response and overall survival. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, developed by Dr Daniel Heng and colleagues, assigns patients to favourable, intermediate or poor risk categories based on six factors available at the time systemic therapy begins: performance status, time from diagnosis to treatment, haemoglobin level, corrected serum calcium, neutrophil count and platelet count [^3]. In the CheckMate 214 trial, five-year overall survival for intermediate and poor risk patients treated with nivolumab plus ipilimumab was 43 percent, compared with 31 percent for sunitinib, demonstrating that IMDC risk group predicts response to immunotherapy-based combinations.

For localised disease treated surgically, the SSIGN score (Stage, Size, Grade and Necrosis) and the Leibovich model use pathological features from the nephrectomy specimen to estimate recurrence risk [^4] [^5]. These scoring systems guide post-operative surveillance intensity. Patients with higher predicted recurrence risk undergo more frequent imaging in the first two to three years after surgery, increasing the chances of detecting recurrence while it remains amenable to metastasectomy or systemic therapy.

The kidney gives rise to several distinct tumour types, each classified under the World Health Organization 5th edition (2022) of urological tumours [^1].

Clear cell renal cell carcinoma accounts for roughly 70 to 80 percent of all kidney cancers in adults. It arises from the proximal tubular epithelium and is characterised by loss of the VHL gene on chromosome 3p through deletion, mutation or promoter methylation. The clear cytoplasm on histology reflects high glycogen and lipid content. Clear cell RCC has the widest range of behaviour, from small indolent tumours found incidentally to rapidly growing masses with vena caval thrombus.

Papillary renal cell carcinoma makes up 10 to 15 percent of cases and is divided into type 1 (small cells, single layer of basophilic cytoplasm, MET driven) and type 2 (large cells, eosinophilic cytoplasm, more aggressive, sometimes linked to fumarate hydratase loss in hereditary leiomyomatosis and renal cell carcinoma syndrome). WHO 2022 now recognises additional papillary patterns including biphasic hyalinising psammomatous RCC.

Chromophobe renal cell carcinoma represents about 5 percent of cases, arises from intercalated cells of the collecting duct, and generally carries a favourable prognosis after surgery. Birt-Hogg-Dube syndrome, caused by germline FLCN mutations, predisposes to chromophobe and hybrid oncocytic tumours.

Collecting duct carcinoma (Bellini duct) is rare, aggressive, and often presents at an advanced stage with lymph node involvement. Renal medullary carcinoma, almost exclusively seen in patients with sickle cell trait, is similarly aggressive and poorly responsive to standard RCC treatments; platinum-based chemotherapy regimens are typically used.

Translocation-associated renal cell carcinomas harbour TFE3 or TFEB gene fusions and are more common in younger patients and children. They can mimic clear cell or papillary morphology and require immunohistochemistry or FISH confirmation.

Other entities in WHO 2022 include ELOC (formerly TCEB1) mutated RCC, succinate dehydrogenase deficient RCC, mucinous tubular and spindle cell carcinoma, and the recently defined eosinophilic solid and cystic RCC. Oncocytoma is benign and does not require staging, though it can be difficult to distinguish from chromophobe RCC on biopsy alone.

Wilms tumour (nephroblastoma) is the primary kidney cancer of childhood and uses a separate staging system under the Children’s Oncology Group and SIOP protocols. It is not covered in detail on this page.

For staging purposes, all adult renal cell carcinoma subtypes use the same AJCC TNM 8e system, but prognosis varies substantially by histology: clear cell has the broadest outcome spectrum, papillary type 1 and chromophobe tend toward better outcomes when localised, and collecting duct and medullary carcinoma carry the poorest prognosis regardless of stage.

Clear cell renal cell carcinoma (ccRCC) accounts for 70 to 80 percent of all kidney cancers in adults worldwide and in the Indian NCR population [^1]. It arises from the proximal convoluted tubule and is characterised by biallelic loss of the VHL gene on chromosome 3p through deletion, mutation, or promoter methylation. VHL loss leads to accumulation of hypoxia-inducible factors (HIF), driving angiogenesis and metabolic reprogramming that produces the high glycogen and lipid content visible as clear cytoplasm on microscopy.

The biological behaviour of clear cell RCC spans a broad spectrum. Small T1a tumours found incidentally on imaging for unrelated complaints often remain indolent for years, with growth rates under 0.3 cm per year. At the other extreme, some clear cell tumours are highly aggressive, invading the renal vein and inferior vena cava (IVC) and spreading to lungs, bones and brain even when the primary mass is only moderately sized. This heterogeneity reflects differences in grade, necrosis content, sarcomatoid features and molecular subtype.

Clear cell RCC is the subtype most responsive to both targeted therapies (VEGFRs and mTOR inhibitors) and immune checkpoint inhibitors, given the high angiogenic burden and often inflamed tumour microenvironment. As a result, patients with metastatic clear cell RCC have seen the most dramatic improvements in survival over the past decade with modern first-line immunotherapy-TKI combinations.

Papillary renal cell carcinoma (pRCC) makes up 10 to 15 percent of adult kidney cancers and is divided into two types based on cell size, cytoplasmic eosinophilia and molecular driver [^1]. Type 1 papillary RCC (small basophilic cells, single layer, MET-driven) generally carries a more favourable prognosis after surgery compared with type 2. Type 2 papillary RCC (large eosinophilic cells, often with sarcomatoid features) is more aggressive and is sometimes associated with loss-of-function mutations in the fumarate hydratase (FH) gene as part of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, which predisposes to early-onset and aggressive type 2 papillary tumours that can metastasise when still small.

Chromophobe renal cell carcinoma represents approximately 5 percent of cases and arises from the intercalated cells of the collecting duct. Tumours show a distinctive pale “plant cell-like” morphology with a prominent cell membrane (binucleate cells). Chromophobe RCC generally carries a favourable prognosis after nephrectomy even at higher stages. Birt-Hogg-Dube (BHD) syndrome, caused by germline FLCN mutations, predisposes to chromophobe and hybrid oncocytic tumours alongside lung cysts and spontaneous pneumothorax.

Collecting duct carcinoma (Bellini duct carcinoma) is rare (less than 1 percent of kidney cancers) but highly aggressive. It frequently presents with lymph node involvement and distant metastases. Median overall survival is poor even after aggressive multimodal treatment. Platinum-based chemotherapy (gemcitabine-cisplatin) is preferred over standard RCC therapies for this histology.

Renal medullary carcinoma is a highly aggressive type found almost exclusively in patients with sickle cell trait or sickle cell disease. It typically presents at an advanced stage and shows poor responsiveness to standard VEGFR-TKI and immune checkpoint inhibitor therapies. Platinum-based chemotherapy is the standard approach when systemic therapy is needed.

Translocation-associated renal cell carcinomas harbour TFE3 or TFEB gene fusions and account for a small percentage of kidney cancers, particularly in younger patients and children. These tumours can mimic clear cell or papillary morphology histologically and require immunohistochemistry or fluorescence in situ hybridisation (FISH) for definitive diagnosis.

Hereditary kidney cancer syndromes account for roughly 5 to 8 percent of all RCC cases and are particularly important to identify because they affect screening strategies, surgical planning, family counselling and risk stratification [^10] [^11] [^12].

Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumour suppressor gene on chromosome 3p25. It predisposes to bilateral and multifocal clear cell RCC, which develops in approximately 80 percent of VHL patients by age 60. VHL disease also causes central nervous system haemangioblastomas, retinal haemangioblastomas, phaeochromocytomas (sometimes familial and occasionally malignant) and pancreatic neuroendocrine tumours. Kidney cancer screening in VHL families typically begins in the teenage years with annual renal ultrasound or MRI.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is caused by fumarate hydratase (FH) loss-of-function mutations. It predisposes to aggressive type 2 papillary RCC and collecting duct carcinoma. The kidney tumours in HLRCC can metastasise when the primary mass is still relatively small (sometimes under 4 cm), making early detection and treatment critical. Affected individuals also develop cutaneous and uterine leiomyomas. FH-deficient RCC shows distinctive papillary architecture with eosinophilic cells and is identifiable by FH immunohistochemistry loss in the pathology specimen.

Birt-Hogg-Dube (BHD) syndrome is caused by germline mutations in the FLCN gene and predisposes to chromophobe RCC, hybrid oncocytic tumours, pulmonary cysts (with risk of spontaneous pneumothorax) and benign skin lesions (fibrofolliculomas). Kidney cancer develops in approximately 30 to 40 percent of BHD patients.

Hereditary papillary renal cell carcinoma (hPRCC) is driven by activating germline MET mutations and causes bilateral, multifocal type 1 papillary RCC. Affected individuals tend to have longer life expectancy than those with sporadic RCC because type 1 papillary tumours are generally indolent.

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma arises in patients with germline mutations in SDHB, SDHC or SDHD genes. SDHB mutations carry the highest kidney cancer risk. SDH-deficient RCC is aggressive and can be associated with paraganglioma-phaeochromocytoma and gastrointestinal stromal tumours (Carney-Stratakis syndrome).

Tuberous sclerosis complex (TSC) is caused by TSC1 or TSC2 mutations and primarily causes benign angiomyolipomas (AMLs) in the kidneys. However, TSC also predisposes to eosinophilic solid and cystic RCC (ESC-RCC), a rare kidney cancer subtype.

BAP1 tumour predisposition syndrome is caused by germline BAP1 mutations and increases risk for clear cell RCC alongside uveal melanoma and mesothelioma. BAP1-mutated tumours can be identified by loss of BAP1 protein on immunohistochemistry.

National Cancer Institute guidelines and NCCN recommendations suggest genetic counselling referral for patients diagnosed before age 46, those with bilateral or multifocal tumours, those with a first degree relative with kidney cancer, and those whose histology suggests a hereditary pattern [^10].

The T (tumour) descriptor in the AJCC TNM system for kidney cancer describes the size of the primary tumour and the extent of local invasion [^2]. It forms the foundation of the stage assignment for localised disease.

T1: Tumour is confined to the kidney and is 7 cm or smaller in greatest dimension. T1 is subdivided into T1a (4 cm or smaller) and T1b (larger than 4 cm but not more than 7 cm). T1 tumours have no invasion beyond the renal capsule or into the renal sinus fat.

T2: Tumour is confined to the kidney but exceeds 7 cm. T2 is subdivided into T2a (more than 7 cm but not more than 10 cm) and T2b (larger than 10 cm). Like T1, T2 tumours do not invade beyond the kidney.

T3: Tumour extends beyond the kidney into the renal vein, the inferior vena cava, or the surrounding adipose tissue. T3 is further subdivided: T3a indicates extension into the renal vein or its segmental branches, the collecting system, the perirenal fat, or the renal sinus fat without crossing Gerota fascia. T3b indicates tumour thrombus in the inferior vena cava below the diaphragm. T3c indicates tumour thrombus extending into the IVC above the diaphragm or through the wall of the IVC. Patients with T3 disease often require complex surgical planning when IVC involvement is present.

T4: Tumour extends beyond Gerota fascia, the fibrous envelope that surrounds the kidney and adrenal gland. T4 indicates direct invasion into the ipsilateral adrenal gland or through Gerota fascia into surrounding structures such as the psoas muscle, posterior peritoneum or abdominal wall.

The N (regional lymph node) and M (distant metastasis) descriptors complete the TNM classification [^2]. Together with the T descriptor, they determine the overall AJCC stage.

N Descriptor: N0 means that there is no regional lymph node involvement. N1 means that one or more regional (hilar and para-aortic) lymph nodes contain metastatic disease. The size of the enlarged lymph node does not change the N category; even a single node with cancer involvement is N1. The presence of N1 disease significantly worsens prognosis compared to N0 disease at the same T stage.

M Descriptor: M0 means there is no distant metastasis. M1 means distant metastatic disease is present. The most common metastatic sites for kidney cancer are the lungs (50 to 60 percent of patients with metastatic disease), bone (30 to 40 percent), liver, brain and contralateral kidney. Other less frequent sites include adrenal gland, peritoneum and soft tissues.

Stage I kidney cancer consists of tumours confined to the kidney measuring 7 cm or less, with no regional lymph node involvement (N0) and no distant metastasis (M0). It is subdivided into stage Ia (T1a) for tumours 4 cm or smaller, and stage Ib (T1b) for tumours larger than 4 cm but not more than 7 cm.

Prognosis for stage I is favourable. Five-year cancer-specific survival exceeds 90 percent for T1a tumours and is approximately 85 to 90 percent for T1b in contemporary surgical series. The SEER database reports a five-year relative survival rate of approximately 93 percent for localised kidney cancer [^6].

Stage I represents the most common presentation in the NCR among patients whose cancers are found incidentally on imaging done for unrelated reasons. The standard of care for T1a tumours is partial nephrectomy (nephron-sparing surgery), and partial nephrectomy is recommended whenever technically feasible for T1b tumours. Robot-assisted partial nephrectomy (RAPN) has become the dominant approach at high-volume centres in Delhi, Gurgaon and Noida.

For patients who are poor surgical candidates due to age, comorbidities or solitary kidney, active surveillance with serial imaging is a guideline-recommended option. Most T1a masses grow slowly at a median rate of approximately 0.3 cm per year, and progression to metastatic disease during surveillance is rare (fewer than 2 percent).

Stage II kidney cancer consists of tumours confined to the kidney that exceed 7 cm in greatest dimension, with no regional lymph node involvement (N0) and no distant metastasis (M0). It is subdivided into stage IIa (T2a, more than 7 cm but not more than 10 cm) and stage IIb (T2b, larger than 10 cm).

Five-year cancer-specific survival for stage II ranges from approximately 75 to 85 percent after radical nephrectomy, depending on grade, necrosis and subtype. Patients with stage II disease often require radical rather than partial nephrectomy because of tumour size, though partial nephrectomy may still be considered at experienced centres when the tumour location is extremely favourable and the surgeon has expertise in complex partial nephrectomy.

Laparoscopic and robotic-assisted radical nephrectomy are performed at all major NCR uro-oncology units. Open radical nephrectomy is reserved for very large tumours, extensive IVC thrombus or locally advanced disease invading adjacent structures.

Stage III kidney cancer encompasses several distinct configurations. A tumour of any size that extends into the renal vein or its segmental branches, the perirenal fat, the renal sinus fat, or the inferior vena cava below the diaphragm (T3a or T3b) without lymph node involvement is stage III. A tumour of any size (T1-4) with involvement of a single regional lymph node (N1) but no distant metastasis is also stage III, regardless of T category.

T3a indicates extension into the renal vein or its segmental branches, invasion of the pelvicaliceal system, or invasion of the perirenal and/or renal sinus fat but not beyond Gerota fascia. T3b indicates extension into the inferior vena cava below the diaphragm. T3c indicates extension into the IVC above the diaphragm or invasion of the wall of the IVC.

Five-year overall survival for pT3N0M0 disease is approximately 53 to 73 percent depending on the extent of venous involvement. N1 disease (pT1-3N1M0) carries a considerably poorer prognosis, with five-year overall survival of roughly 20 to 40 percent.

Patients with renal vein or IVC thrombus require complex surgical planning. Those with supradiaphragmatic thrombus (T3c) involving the right atrium may need a combined cardiothoracic approach with cardiopulmonary bypass. In the NCR, such complex thrombectomies are managed at leading cancer centres in the region Memorial Gurgaon, where uro-oncology and cardiothoracic surgery teams operate together.

Stage IV kidney cancer includes two categories: T4N0M0 disease (tumours that have grown beyond Gerota fascia or into the ipsilateral adrenal gland by contiguous extension) and any tumour with distant metastasis (M1), regardless of T and N status.

The most common metastatic sites are lung (50 to 60 percent of metastatic patients), bone (30 to 40 percent), liver, brain and contralateral kidney. SEER data report a five-year relative survival of approximately 16 to 17 percent for distant-stage kidney cancer, though outcomes vary widely based on IMDC risk group and the treatment received [^6].

Patients in the IMDC favourable risk group treated with modern immunotherapy-TKI combinations can achieve median overall survival exceeding four years, while poor-risk patients have a median closer to one year. The distinction between T4N0M0 disease and M1 disease is important, as some T4N0M0 patients (disease extending beyond Gerota but without distant spread) may be candidates for aggressive surgical resection of the primary tumour, whereas M1 patients require systemic therapy as the foundation of treatment.

Once kidney cancer has spread, the TNM stage alone does not drive treatment selection. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, published by Dr Daniel Heng and colleagues, assigns patients to favourable, intermediate or poor risk groups based on six clinical and laboratory factors assessed at the start of systemic therapy [^3].

The six risk factors are: Karnofsky performance status below 80 percent, time from diagnosis to treatment initiation less than one year, haemoglobin below the lower limit of normal (typically less than 13.0 g/dL), corrected serum calcium above the upper limit of normal, neutrophil count above the upper limit of normal, and platelet count above the upper limit of normal.

Patients with zero risk factors are classified as favourable risk. Those with one or two factors fall into the intermediate risk group, and those with three or more are poor risk. These categories powerfully predict overall survival. In the CheckMate 214 trial, five-year overall survival for intermediate and poor risk patients treated with nivolumab plus ipilimumab was 43 percent, compared with 31 percent for sunitinib monotherapy [^15].

The IMDC model is used at tumour boards across Delhi, Gurgaon and Noida to select between immunotherapy-based combinations and TKI monotherapy in the first line setting. Patients in the favourable risk category may derive benefit from pembrolizumab plus axitinib or other immuno-TKI combinations without the additional toxicity of dual immunotherapy.

For patients treated with surgery who have no metastatic disease, the SSIGN (Stage, Size, Grade and Necrosis) score and the Leibovich model estimate the probability of recurrence or cancer-specific death using pathological features from the nephrectomy specimen [^4] [^5].

The SSIGN score incorporates TNM stage, tumour size, WHO/ISUP nucleolar grade and presence of coagulative necrosis. Variables are weighted and summed to assign patients to risk groups: low risk (SSIGN 0-2), intermediate risk (SSIGN 3-4), high risk (SSIGN 5-6) and very high risk (SSIGN 7 or higher). Five-year cancer-specific survival ranges from greater than 95 percent in the low risk group to less than 10 percent in the very high risk group in the original Mayo Clinic cohort.

The Leibovich model uses similar variables (TNM stage, size, grade) and adds the presence of sarcomatoid differentiation and regional lymph node status. It produces risk groups with distinct survival curves.

These tools help guide the intensity of post-surgical surveillance imaging. Higher-risk patients undergo more frequent CT scans in the first two to three years after nephrectomy to increase the likelihood of detecting recurrent disease while it remains amenable to treatment.

Kidney cancer has earned a reputation as a “silent” tumour because early stages rarely cause symptoms. In the era of widespread abdominal imaging, roughly 60 percent of kidney cancers in urban Indian centres are found incidentally on an ultrasound or CT done for an unrelated complaint such as gallstones, vague abdominal discomfort or a pre-employment health check.

The classic triad taught in textbooks is flank pain, visible blood in the urine (gross haematuria) and a palpable abdominal mass. In practice, all three occur together in fewer than ten percent of patients, and when they do, the disease is usually locally advanced.

Haematuria is the single most common symptom that brings patients to a urologist. It can be painless and intermittent, appearing for a day and then resolving for weeks, which sometimes leads patients to dismiss it. Any episode of visible blood in the urine in an adult over forty warrants an ultrasound and urine cytology at a minimum.

Flank or loin pain develops when the tumour stretches the renal capsule, invades perirenal fat, or causes clot colic by bleeding into the collecting system. Some patients describe a dull persistent ache rather than sharp pain.

A palpable mass in the flank or abdomen is now uncommon at first presentation in metropolitan settings but is still seen in patients who have deferred evaluation for months.

Constitutional symptoms, including unexplained weight loss, persistent low grade fever, fatigue and loss of appetite, indicate more advanced disease. Kidney cancer can produce paraneoplastic syndromes: erythrocytosis from ectopic erythropoietin production, hypercalcaemia from parathyroid hormone related peptide, hepatic dysfunction without liver metastases (Stauffer syndrome), and secondary amyloidosis. These can be the presenting feature before the kidney mass is detected.

New onset varicocele on the left side in a man, particularly if it does not reduce when lying flat, can indicate tumour thrombus in the left renal vein and should prompt imaging.

Metastatic disease may present first. Bone pain in the hip, spine or shoulder, a pathological fracture, haemoptysis from a lung deposit, or seizures and headaches from brain involvement occasionally lead to the diagnosis before the primary kidney tumour is known.

In the NCR context, patients with any of these presentations are typically seen first at a general physician or local diagnostic lab, where an ultrasound picks up a renal mass. Referral then goes to a urologist or uro-oncologist at centres such as a tertiary cancer centre, a tertiary cancer centre Rohini, a leading cancer centre Gurgaon, a leading cancer centre Saket, a leading cancer centre Memorial Gurgaon, a leading cancer centre Indraprastha, a leading cancer centre or a leading cancer centre. Incidental detection on cross-sectional imaging has increased substantially in the past decade as CT and MRI access has expanded across Delhi, Gurgaon and Noida.

No single cause explains kidney cancer in most patients. The disease arises from acquired mutations in the epithelial cells of the renal tubule, and a number of factors increase the probability of these mutations accumulating.

Tobacco smoking is the most consistently identified modifiable risk factor. The International Agency for Research on Cancer classifies tobacco as a Group 1 carcinogen for the renal pelvis and has noted sufficient evidence linking smoking to renal cell carcinoma [^7]. Current smokers face roughly a 50 percent higher risk than never-smokers, with a dose-response relationship. The risk declines after quitting but takes more than fifteen years to approach baseline.

Obesity has been classified by IARC as a risk factor for kidney cancer, with a linear relationship between body mass index and risk [^8]. Adiposity is thought to drive tumour development through chronic inflammation, insulin resistance, altered sex hormone metabolism and elevated levels of insulin-like growth factor 1. In India, the rising prevalence of overweight and metabolic syndrome, particularly in urban NCR populations, has paralleled the increasing incidence of kidney cancer.

Hypertension is independently associated with RCC risk, and the association persists after adjusting for BMI and antihypertensive medications. Whether the risk comes from the elevated blood pressure itself or from the underlying vascular and metabolic changes is not fully settled.

Chronic kidney disease and acquired cystic kidney disease, especially in patients on long-term haemodialysis, carry a substantially elevated risk. The native kidneys of dialysis patients develop multiple cysts over years, and the lining cells of these cysts can undergo malignant transformation, most often to papillary RCC. Screening with ultrasound is recommended for patients who have been on dialysis for three years or more.

Occupational exposures include trichloroethylene, a chlorinated solvent used in metal degreasing and dry cleaning, which IARC classifies as a Group 1 carcinogen with sufficient evidence for kidney cancer [^9]. Cadmium, certain pesticides and gasoline exposure have been investigated with less conclusive results.

Hereditary kidney cancer syndromes account for roughly 5 to 8 percent of all cases and are particularly important to identify. Von Hippel-Lindau disease, hereditary leiomyomatosis and renal cell carcinoma syndrome, Birt-Hogg-Dube syndrome, hereditary papillary renal cell carcinoma, succinate dehydrogenase deficient RCC, tuberous sclerosis complex and BAP1 tumour predisposition syndrome all increase kidney cancer risk.

In the Indian context, the ICMR NCRP population-based cancer registries have documented a rising age-adjusted incidence rate for kidney cancer in urban registries including Delhi over the past two decades, consistent with global trends [^13]. The a tertiary cancer centre and a tertiary cancer centre urology departments note that the proportion of incidentally detected early stage tumours has increased with wider availability of ultrasound and CT, but a substantial number of patients in the NCR still present with locally advanced or metastatic disease, particularly those referred from smaller towns in Uttar Pradesh, Haryana and Rajasthan.

Most kidney cancers in Delhi, Gurgaon and Noida are found during imaging done for another reason. An ultrasound ordered for abdominal pain, a routine health check or a pre-operative scan picks up a solid mass in the kidney, and the chain of evaluation begins from there. When a renal mass is suspected or confirmed, the diagnostic workup follows a structured path through imaging, laboratory tests, and in selected cases, tissue biopsy.

Contrast-enhanced CT of the abdomen and pelvis is the primary staging investigation. A triphasic renal protocol CT acquires images before contrast, during the corticomedullary phase (when the cortex enhances brightly) and during the nephrographic phase (when the entire parenchyma enhances uniformly). This protocol shows tumour size, location within the kidney, extension into perirenal fat or the renal vein, lymph node enlargement and visceral metastases. Enhancement of 15 Hounsfield units or more after contrast injection distinguishes a solid renal mass from a simple cyst with high reliability.

MRI of the abdomen is used when CT is contraindicated (contrast allergy, advanced chronic kidney disease, pregnancy) or when the nature of a complex cystic lesion remains uncertain on CT. MRI is also the preferred modality for evaluating the cranial extent of inferior vena cava tumour thrombus because it shows the relationship between thrombus and the right atrium without ionising radiation.

CT of the chest is recommended for staging the lungs, as the lung is the most common distant metastatic site for renal cell carcinoma. When the primary tumour is small and localised on initial imaging, a plain chest radiograph may be acceptable, but CT is more sensitive for sub-centimetre pulmonary nodules.

Brain MRI is not part of routine staging for asymptomatic patients. It is performed when neurological symptoms such as headache, seizure or focal deficit suggest intracranial disease.

Bone scintigraphy is indicated when there is bone pain, elevated alkaline phosphatase, or other clinical suspicion of skeletal metastases.

FDG PET-CT has a limited role in primary renal cell carcinoma staging because the kidney excretes the tracer, which can obscure a renal mass. PET-CT is used selectively when there is concern about widespread metastatic disease or when conventional imaging gives equivocal results. In the NCR, PET-CT facilities are available at a tertiary cancer centre, a tertiary cancer centre Rohini, a leading cancer centre Saket, a leading cancer centre Vaishali, a leading cancer centre Memorial Gurgaon, leading cancer centres Indraprastha and several standalone imaging centres.

Baseline blood work includes a complete blood count, serum creatinine and estimated glomerular filtration rate, liver function tests, serum calcium, lactate dehydrogenase, coagulation profile, and urinalysis. These values feed into the IMDC risk model for patients with metastatic disease.

A DTPA or MAG3 renal scan (split renal function study) is performed when there is any doubt about the function of the contralateral kidney or when the tumour is large enough to affect the ipsilateral kidney. Knowing the split function helps the surgeon decide whether a partial nephrectomy is feasible or whether the patient can tolerate a radical nephrectomy without being left with insufficient renal reserve.

Cross-sectional imaging forms the backbone of kidney cancer diagnosis and staging. Each modality offers distinct advantages depending on the clinical scenario.

Contrast-enhanced CT with a triphasic renal protocol remains the workhorse for primary detection and staging. The corticomedullary phase (obtained at peak cortical enhancement, typically 25-35 seconds after intravenous contrast injection) clearly delineates tumours from normal parenchyma and shows renal arterial involvement. The nephrographic phase (60-80 seconds) provides uniform parenchymal enhancement and is better for evaluating the extent of invasion into perirenal fat and the renal vein. Enhancement of 15 HU or greater reliably identifies solid tumours; enhancement less than 10 HU suggests a cyst. A non-enhancing mass may indicate necrotic tumour, cystic degeneration or oncocytoma. Multi-detector CT allows thin section imaging and multiplanar reformatting, essential for surgical planning when IVC thrombus or complex renal anatomy is present.

MRI excels in specific settings. T2-weighted sequences show anatomy without gadolinium, useful in patients with contrast allergy or significant renal impairment. Dynamic contrast-enhanced MRI with gadolinium provides tumour enhancement characteristics similar to CT but with better soft tissue differentiation. MRI is the gold standard for assessing the cranial extent of IVC thrombus and for determining whether thrombus extends to the right atrium, information that guides whether a surgical approach requires cardiopulmonary bypass. MRI is also superior for evaluating complex cystic lesions and for detecting small metastases in the adrenal gland or liver.

Chest CT is the standard for lung staging because it detects sub-centimetre nodules that plain radiography misses. In patients with metastatic disease, accurate lung staging is essential for treatment planning and prognostication.

FDG PET-CT has limited utility in primary RCC because renal excretion of fluorodeoxyglucose limits sensitivity for renal masses. Some non-clear cell subtypes (especially collecting duct and medullary carcinoma) show higher FDG avidity, but the test is not recommended for routine staging. PET-CT is useful for evaluating equivocal bone lesions in patients with metastatic disease or when there is concern for widespread disease that might be missed on conventional imaging.

Renal scintigraphy (DTPA or MAG3 split renal function study) quantifies the percentage of total renal function attributable to each kidney, usually expressed as the function of the contralateral kidney as a percentage of total GFR. A contralateral kidney with greater than 40 to 45 percent of total function generally provides sufficient reserve to tolerate loss of the diseased kidney, whereas lower function may argue for nephron-sparing surgery if feasible.

The surgical specimen or biopsy core is assessed by a genitourinary pathologist. The report includes histological subtype (according to WHO 2022 classification), WHO/ISUP nucleolar grade (grades 1 through 4, replacing the older Fuhrman system), presence or absence of sarcomatoid or rhabdoid features, presence of tumour necrosis, margin status, and pathological TNM stage.

Immunohistochemistry panels help distinguish subtypes when morphology alone is ambiguous. PAX8 positivity confirms renal origin. CA-IX, vimentin and CD10 support clear cell RCC. CK7 and AMACR patterns differentiate papillary subtypes. KIT (CD117) and parvalbumin mark chromophobe RCC. TFE3 and TFEB immunostains or FISH are used to identify translocation-associated tumours. Fumarate hydratase (FH) and succinate dehydrogenase B (SDHB) stains are performed when hereditary syndromes are suspected.

Somatic genomic profiling is not routinely required for localised kidney cancer, but is relevant in the metastatic setting when there is a need to identify actionable mutations or confirm VHL status. Next-generation sequencing panels that include VHL, PBRM1, BAP1, SETD2, KDM5C, MTOR, TSC1, TSC2, MET and PTEN are available through reference labs such as MedGenome, Strand Life Sciences and through in-house molecular pathology at leading cancer centres in the region.

Partial nephrectomy (nephron-sparing surgery) is the preferred operation for cT1a tumours (up to 4 cm) and is recommended whenever technically feasible for T1b tumours up to 7 cm, as long as a negative margin can be achieved while preserving sufficient renal parenchyma. The oncological outcomes of partial nephrectomy are equivalent to radical nephrectomy for T1 tumours, and the preserved kidney function reduces the long-term risk of cardiovascular events and chronic kidney disease progression.

Robot-assisted partial nephrectomy (RAPN) has become the dominant approach in high-volume NCR centres. The Indian Robotic Partial Nephrectomy Collaborative Group published a multicentre analysis of 1,267 Indian patients across 14 centres showing trifecta attainment (negative margins, no major complications, warm ischaemia time under 25 minutes) in 61 percent [^14]. RAPN is available on Da Vinci Xi platforms at a leading cancer centre Gurgaon, a leading cancer centre Saket, a leading cancer centre Memorial Gurgaon, leading cancer centres (for selected cases), a leading cancer centre Indraprastha and several other NCR hospitals. Open and laparoscopic partial nephrectomy remain valid alternatives, particularly when robotic access is limited or tumour complexity is very high.

Recovery after RAPN is typically faster than open surgery, with hospitalisation averaging 3 to 5 days and return to normal activity within 4 to 6 weeks. Perioperative blood loss is lower with robotic technique, reducing transfusion requirements.

Radical nephrectomy is indicated for tumours larger than 7 cm (T2), for tumours with renal vein or IVC involvement (T3), when partial nephrectomy is not technically feasible, and when the contralateral kidney has normal function. Laparoscopic and robotic radical nephrectomy are performed at all major NCR uro-oncology units; open radical nephrectomy is reserved for very large tumours, extensive IVC thrombus or locally advanced disease invading adjacent structures.

IVC thrombectomy is required when tumour thrombus extends into the inferior vena cava. The level of thrombus is classified as follows: level I is infrahepatic IVC (below the hepatic veins), level II is hepatic vein level, level III is intrahepatic IVC, and level IV is supradiaphragmatic IVC or right atrium.

For level I and II thrombus, the procedure is performed through an abdominal approach with vascular control. Level III thrombus requires liver mobilisation and potentially a thoraco-abdominal approach. Level IV thrombus, which extends above the diaphragm or into the right atrium, is the most challenging and may require collaboration with cardiac surgery and use of cardiopulmonary bypass. In the NCR, level III and IV thrombectomies are managed at leading cancer centres in the region Memorial Gurgaon, where uro-oncology and cardiothoracic surgery teams operate together.

Percutaneous cryoablation and radiofrequency ablation (RFA) are alternatives to partial nephrectomy for small renal masses (generally T1a, up to 4 cm) in patients who are poor surgical candidates due to age, comorbidities, solitary kidney with limited reserve, or bilateral tumours. Cryoablation uses argon gas to freeze the tumour through probes placed under CT or ultrasound guidance. RFA uses heat delivered through an electrode.

Local recurrence rates are higher than for surgical excision (approximately 5 to 10 percent at five years compared with 1 to 3 percent for partial nephrectomy), so ablation is reserved for patients in whom surgery carries disproportionate risk. The DISSRM registry, a prospective multicentre study comparing active surveillance with intervention for clinical T1a renal masses, has enrolled patients undergoing ablation as one arm and provides ongoing safety and oncological data [^29].

Ablation services are available in the NCR through interventional radiology at leading cancer centres in the region Saket, a leading cancer centre and a leading cancer centre Memorial Gurgaon.

Active surveillance is a management strategy for patients with small renal masses (clinical T1a, up to 4 cm) who are elderly, have significant competing comorbidities, or prefer to avoid immediate intervention. The approach involves serial abdominal imaging (typically CT or MRI every three to six months initially, then annually) to monitor the growth rate of the mass. Most small renal masses grow slowly, at a median rate of about 0.3 cm per year in published series. Fewer than 2 percent of surveilled masses progress to metastatic disease.

Active surveillance does not preclude later intervention. If the tumour demonstrates rapid growth (more than 0.5 cm per year), reaches 4 cm, or develops concerning features on imaging, the patient can proceed to surgery or ablation with curative intent. The American Society of Clinical Oncology and the NCCN guidelines both include active surveillance as a category 2A recommendation for appropriately selected patients.

Systemic treatment for metastatic renal cell carcinoma has transformed over the past two decades, moving from cytokine-era interferon and interleukin-2 to targeted therapy with TKIs and mTOR inhibitors, and now to immunotherapy-based combinations in the first line.

Five immunotherapy-based regimens have demonstrated superiority over sunitinib monotherapy in randomised phase 3 trials and form the backbone of first-line treatment.

Nivolumab plus ipilimumab (CheckMate 214) is the dual immune checkpoint inhibitor combination (anti-PD-1 plus anti-CTLA-4) and is the standard of care for intermediate and poor risk IMDC patients [^15]. At five-year follow-up, overall survival was 43 percent versus 31 percent for sunitinib in the intermediate/poor risk population, with an 11 percent complete response rate. Nivolumab is given at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every three weeks for four induction cycles, followed by nivolumab 480 mg every four weeks as maintenance.

Pembrolizumab plus axitinib (KEYNOTE-426) is an anti-PD-1 plus VEGFR-TKI combination that showed improved overall survival, progression-free survival and objective response rate across all IMDC risk groups compared with sunitinib [^16]. Median OS exceeded 45 months in the combination arm at extended follow-up. Pembrolizumab 200 mg IV every three weeks is given alongside axitinib 5 mg orally twice daily.

Nivolumab plus cabozantinib (CheckMate 9ER) is a combination of anti-PD-1 with a multi-target TKI (VEGFR, MET, AXL) [^17]. It demonstrated improved PFS (16.6 versus 8.3 months), OS and ORR compared with sunitinib across all risk groups. Nivolumab 240 mg IV every two weeks is given with cabozantinib 40 mg orally daily.

Pembrolizumab plus lenvatinib (CLEAR) achieved the highest objective response rate among first-line trials (71 percent) and showed improved PFS and OS versus sunitinib [^18]. However, the regimen has a higher rate of grade 3 or higher adverse events compared with other combinations, requiring careful toxicity management. Pembrolizumab 200 mg IV every three weeks is given with lenvatinib 20 mg orally daily.

Avelumab plus axitinib (JAVELIN Renal 101) is an anti-PD-L1 plus TKI combination that improved PFS over sunitinib but has not yet demonstrated a statistically significant OS benefit [^19]. It is used less frequently than the four combinations above.

For IMDC favourable risk patients specifically, pembrolizumab plus axitinib, nivolumab plus cabozantinib, and pembrolizumab plus lenvatinib are all options, as the CheckMate 214 dual immunotherapy regimen did not show a significant OS advantage in the favourable risk subgroup.

After progression on first-line immunotherapy-based combination therapy, the most commonly used second-line options include: cabozantinib monotherapy (METEOR trial: improved PFS of 7.4 versus 3.9 months and improved OS compared with everolimus after prior VEGFR-TKI) [^20]; lenvatinib plus everolimus (Study 205: improved PFS of 14.6 months versus 5.5 months for everolimus alone) [^21]; nivolumab monotherapy (CheckMate 025: improved OS of 25.0 versus 19.6 months compared with everolimus after prior TKI) [^22]; axitinib monotherapy (AXIS trial: improved PFS of 6.7 versus 4.7 months versus sorafenib after first-line therapy) [^23]; and everolimus (RECORD-1: demonstrated PFS benefit over placebo) [^24].

TKI monotherapy with sunitinib or pazopanib remains an option for patients who have not yet received a TKI.

Belzutifan, a first-in-class HIF-2-alpha inhibitor, received approval for previously treated advanced clear cell RCC based on the LITESPARK-005 trial, which showed improved PFS compared with everolimus and an objective response rate of 22 percent versus 3.5 percent [^25]. LITESPARK-004 demonstrated durable responses in VHL disease-associated RCC. Belzutifan combined with lenvatinib is under evaluation in the LITESPARK-011 trial for patients who have received prior immunotherapy.

Non-clear cell renal cell carcinomas (papillary, chromophobe, collecting duct, translocation, unclassified) are less common and were excluded from most landmark phase 3 trials. Cabozantinib has activity across non-clear cell subtypes and is a preferred option; a phase 2 trial of cabozantinib plus nivolumab in non-clear cell RCC showed an objective response rate of 48 percent. Sunitinib and temsirolimus have shown modest activity in non-clear cell disease. For collecting duct and medullary carcinoma, platinum-based chemotherapy (gemcitabine plus cisplatin) is used given the poor response to standard RCC therapies. Immune checkpoint inhibitors are increasingly used off-label for non-clear cell subtypes based on basket trial data and retrospective series.

Pembrolizumab is the first and, as of 2025, the only adjuvant therapy to demonstrate an overall survival benefit in kidney cancer. The KEYNOTE-564 trial randomised patients with clear cell RCC at increased risk of recurrence after nephrectomy (pT2 grade 4 or sarcomatoid, pT3, pT4, or pN1, or M1 rendered no evidence of disease after surgery) to pembrolizumab 200 mg IV every three weeks for up to one year versus placebo [^26].

At the 2024 analysis published in the New England Journal of Medicine, the trial showed a statistically significant improvement in overall survival (HR 0.62, 95% CI 0.44 to 0.87, with four-year OS 91.2 percent versus 86.0 percent), marking the first time any adjuvant treatment has improved survival after nephrectomy for RCC. Adjuvant pembrolizumab is now recommended by NCCN for eligible patients and is discussed at post-surgical tumour boards across NCR centres.

Other adjuvant trials in kidney cancer have not shown overall survival benefit. The S-TRAC trial (adjuvant sunitinib) showed improved disease-free survival but no overall survival advantage, and it is not widely used. IMmotion010 (atezolizumab), CheckMate 914 (nivolumab plus ipilimumab), and PROSPER (perioperative nivolumab) did not meet their primary endpoints.

The figures below are approximate out-of-pocket ranges observed at private hospitals across the National Capital Region in 2024-2025. Government-empanelled centres (leading cancer centres for BPL patients, Rajiv Gandhi Super Speciality Hospital) charge substantially less, and many procedures are covered at zero cost for eligible beneficiaries under PMJAY or CGHS [^32].

Diagnostic workup: Initial consultation with a urologist or uro-oncologist costs 800 to 2,500 per visit. Ultrasound abdomen (screening or initial detection) is 1,200 to 3,500. Contrast-enhanced CT abdomen and pelvis (triphasic renal protocol) is 6,000 to 15,000. MRI abdomen (for IVC thrombus evaluation or complex cystic lesion) is 10,000 to 22,000. CT chest (lung staging) is 4,000 to 10,000. FDG PET-CT whole body is 15,000 to 28,000. Bone scintigraphy is 5,000 to 10,000. DTPA or MAG3 split renal function study is 4,000 to 8,000. Percutaneous renal mass core biopsy (ultrasound or CT guided, including pathology processing) is 15,000 to 35,000. Histopathology with immunohistochemistry panel is 8,000 to 20,000. Next-generation sequencing panel is 28,000 to 1,20,000 depending on panel breadth. Total diagnostic workup for a typical localised kidney cancer is roughly 40,000 to 90,000 at a private hospital.

Surgery: Robot-assisted partial nephrectomy (RAPN) at a private hospital with Da Vinci Xi is 2,80,000 to 5,50,000. Laparoscopic partial nephrectomy is 1,80,000 to 3,50,000. Open partial nephrectomy is 1,40,000 to 2,80,000. Laparoscopic or robotic radical nephrectomy is 2,00,000 to 4,20,000. Open radical nephrectomy is 1,50,000 to 3,00,000. Level I-II IVC thrombectomy (infrahepatic) adds 50,000 to 1,50,000 over baseline radical nephrectomy cost. Level III-IV thrombectomy (intrahepatic or supradiaphragmatic, with or without cardiopulmonary bypass) is 5,00,000 to 12,00,000 total package. Cytoreductive nephrectomy in metastatic setting is 2,00,000 to 4,50,000. Metastasectomy is 1,50,000 to 5,00,000 depending on the organ involved.

Thermal ablation: Percutaneous cryoablation or radiofrequency ablation for T1a renal mass is 1,20,000 to 2,80,000 at centres offering the service.

Radiation therapy: Palliative external beam radiation for bone metastases is 25,000 to 60,000 per course. SBRT for primary renal tumour or oligometastatic deposits (3 to 5 fractions) is 1,80,000 to 4,50,000. Stereotactic radiosurgery (SRS) for brain metastases is 1,50,000 to 3,50,000 per session. Whole brain radiation therapy (10 fractions) is 60,000 to 1,20,000.

Systemic therapy: Oral TKIs using generic versions from Indian manufacturers have substantially lower costs than originators. Sunitinib 50 mg daily is 4,500 to 18,000 per cycle using generics (versus 50,000 to 70,000 for originator). Pazopanib 800 mg daily is 8,000 to 25,000 per month using generics (versus 45,000 to 60,000 originator). Cabozantinib 40 or 60 mg daily is 4,000 to 13,000 per month using generics (versus 2,80,000 to 3,50,000 originator). Axitinib 5 mg twice daily is 12,000 to 30,000 per month using generics (versus 1,80,000 originator). Lenvatinib 18 or 20 mg daily is 8,000 to 20,000 per month using generics (versus 1,60,000 to 2,00,000 originator). Everolimus 10 mg daily is 6,000 to 15,000 per month using generics (versus 55,000 to 75,000 originator).

Immunotherapy drugs remain at originator pricing. Nivolumab 240 mg IV every 2 weeks is 1,20,000 to 1,80,000 per infusion. Pembrolizumab 200 mg IV every 3 weeks is 1,50,000 to 2,50,000 per infusion. In combination regimens, monthly costs range from 1,80,000 to 2,80,000 per month for nivolumab-based, pembrolizumab-based or cabozantinib combinations. For adjuvant pembrolizumab (KEYNOTE-564 regimen), up to 17 cycles over one year total roughly 25,00,000 to 40,00,000 for the full course [^31] [^35].

Financial support and entitlements: Pradhan Mantri Jan Arogya Yojana (PMJAY, Ayushman Bharat) covers up to 5 lakh per family per year at empanelled hospitals [^32]. The Health Benefits Package 2.0 lists surgical oncology packages including nephrectomy (radical and partial), and medical oncology packages covering chemotherapy cycles. Immunotherapy drugs are not separately listed in PMJAY packages at most empanelled centres as of 2024-2025. Central Government Health Scheme (CGHS) covers cancer treatment at CGHS-empanelled hospitals for central government employees and pensioners. a tertiary cancer centre operates outside the CGHS rate card and is free or heavily subsidised for all patients. Ex-Servicemen Contributory Health Scheme (ECHS) covers cancer treatment for defence personnel and dependants. Employees’ State Insurance Corporation (ESIC) covers workers in the organised sector. Delhi Arogya Kosh provides financial assistance up to 5 lakh for BPL and lower income group residents of Delhi. Rashtriya Arogya Nidhi (RAN) provides one-time financial assistance up to 15 lakh for BPL patients. Prime Minister’s National Relief Fund (PMNRF) accepts applications for financial support for cancer treatment on a case-by-case basis. Haryana Mukhyamantri Cancer Parivar Sahayata Yojana provides financial support for Haryana residents. UP Mukhyamantri Jan Arogya Yojana extends coverage at state-empanelled facilities for UP residents. Hospital trust and NGO support includes the a tertiary cancer centre patient welfare fund, Indian Cancer Society, CanSupport (Delhi), Cuddles Foundation and pharmaceutical company patient assistance programmes.

Q: What should I expect in the first week after a kidney cancer diagnosis in the NCR?

The initial period after diagnosis usually involves completing the staging workup. If a renal mass was found on ultrasound, your urologist will order a triphasic CT of the abdomen and pelvis, a CT of the chest, and baseline blood work. These tests can usually be done within 3 to 5 working days at any major hospital in Delhi, Gurgaon or Noida. If the tumour is localised, a surgery date is typically scheduled within 2 to 4 weeks. If the imaging suggests advanced disease, a biopsy may be performed and a referral to medical oncology follows to discuss systemic therapy options. Kidney cancer is not a surgical emergency in most cases, so there is time to gather reports, seek a second opinion and make informed decisions.

Q: Should I get a second opinion before starting treatment?

A second opinion is a reasonable step, particularly for locally advanced or metastatic disease where the choice between different systemic therapy combinations affects both outcomes and cost. For straightforward localised tumours (stage I, T1a), where the standard recommendation is partial nephrectomy, the treatment path is well-established and a second opinion may not change the plan but can still offer reassurance. For complex cases such as IVC thrombus, bilateral tumours, solitary kidney, or hereditary syndromes, a second review at a centre with high-volume uro-oncology experience (leading cancer centres Mumbai for referral) is worth pursuing. Bring the actual CT scan images (on CD or uploaded to a DICOM viewer), the pathology slides if a biopsy was done, and all blood reports. A verbal summary alone is not sufficient for a meaningful second opinion.

Q: Is robotic surgery actually better than open surgery for kidney cancer?

For partial nephrectomy on a T1 tumour, the robotic approach (RAPN) offers advantages in terms of shorter hospital stay, less blood loss, faster recovery and comparable oncological outcomes in experienced hands. The IRPN Collaborative Group data from Indian centres show good trifecta results. However, the type of surgery matters less than whether the surgeon performs the operation regularly and whether the goal of nephron-sparing (preserving kidney tissue) is achieved with clear margins. An experienced open partial nephrectomy at a high-volume centre produces equivalent cancer control to a robotic partial at another centre. For radical nephrectomy, the difference between robotic/laparoscopic and open approaches is less pronounced, as the operation involves removing the entire kidney. Ask your surgeon about their case volume and complication rates rather than focusing solely on whether a robot is used.

Q: How do I verify my doctor’s credentials and the hospital’s accreditation?

Check the surgeon’s registration on the National Medical Commission (NMC) register at nmc.org.in. For Delhi-based doctors, the Delhi Medical Council register is searchable online. For Haryana (Gurgaon), check the Haryana Medical Council; for Uttar Pradesh (Noida), the UP Medical Council. Hospital accreditation can be verified through the National Accreditation Board for Hospitals and Healthcare Providers (NABH) at nabh.co. NABH accreditation indicates that the hospital meets national quality and safety standards. For cancer-specific infrastructure, ask whether the hospital has a dedicated uro-oncology unit, whether tumour board meetings are held regularly, and whether the pathology department has WHO/ISUP grading and IHC capability in-house.

Q: What is the difference between originator (branded) and generic TKI drugs for kidney cancer?

The oral targeted therapy drugs used in kidney cancer, such as sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib and everolimus, are available in India as licensed generics manufactured by companies such as Natco, Cipla, Dr Reddy’s, Hetero and Glenmark. These generics contain the same active pharmaceutical ingredient at the same dose as the originator product and are approved by the Central Drugs Standard Control Organisation (CDSCO). The price difference is substantial: generic cabozantinib costs roughly 4,000 to 13,000 per month compared to 2,80,000 or more for originator Cabometyx. Generic sunitinib costs 4,500 to 18,000 per cycle compared to 50,000 to 70,000 for Sutent. Your medical oncologist can prescribe the generic version, and for most patients in the NCR, generics are the standard of care for oral TKIs. Immunotherapy drugs (nivolumab, pembrolizumab, ipilimumab) do not yet have Indian biosimilars for RCC indications, so these remain at originator pricing.

Q: Can I use PMJAY (Ayushman Bharat) for kidney cancer surgery and treatment?

PMJAY covers nephrectomy (both radical and partial) and radiation therapy under its surgical and radiation oncology packages at empanelled hospitals. Medical oncology chemotherapy cycles are also covered. However, newer immunotherapy combinations (such as nivolumab-ipilimumab or pembrolizumab-axitinib) may not be fully covered under current PMJAY package rates, as the per-cycle cost of these regimens exceeds the package ceilings at many empanelled centres. If your treatment plan involves immunotherapy, discuss the PMJAY coverage gap with your hospital’s billing and social work department early. For patients who are not PMJAY-eligible, CGHS, ECHS, Delhi Arogya Kosh (Delhi residents only), Rashtriya Arogya Nidhi, and pharmaceutical company patient assistance programmes are alternatives worth exploring.

Q: Is active surveillance safe for a small kidney mass?

For tumours 4 cm or smaller (clinical T1a) in patients who are elderly or have significant comorbidities, active surveillance with serial imaging is a recognised and guideline-supported option (NCCN category 2A, ASCO recommendation). Most small renal masses grow slowly, at a median of about 0.3 cm per year, and fewer than 2 percent progress to metastatic disease during surveillance. If the tumour grows beyond 4 cm or shows rapid growth (more than 0.5 cm per year), surgery or ablation can still be performed with curative intent. Active surveillance does not mean doing nothing; it means structured monitoring with CT or MRI every 3 to 6 months initially, then annually. Your urologist should explain the specific imaging schedule and the criteria that would trigger intervention.

Q: What about clinical trials for kidney cancer in India?

Clinical trials for advanced RCC are open at select centres in India, primarily a tertiary cancer centre Mumbai, a tertiary cancer centre Delhi and a tertiary cancer centre Rohini [^36]. Trial availability changes frequently. The Clinical Trials Registry of India (ctri.nic.in) lists currently recruiting studies. Your medical oncologist can check whether you are eligible for any open trial based on your histology, prior treatment, and current disease status. Trial participation provides access to investigational drugs (such as belzutifan combinations or novel agents) at no drug cost to the patient, with close monitoring. Ask your treating team whether any relevant trials are open.

Q: Does kidney cancer come back after surgery?

Recurrence risk depends on the stage and pathological features of the tumour removed. For stage I tumours (T1, N0, M0), the risk of recurrence after complete surgical excision is low, generally under 10 percent at five years. For stage II and III tumours, recurrence risk rises to 20 to 40 percent or higher depending on grade, necrosis and sarcomatoid features. The SSIGN and Leibovich scoring tools estimate individual recurrence probability and guide surveillance intensity. Post-surgery follow-up involves periodic CT scans (typically every 6 months for the first 2 to 3 years, then annually) and blood work. For patients at higher risk of recurrence (pT2 grade 4, pT3, pT4, N1, or M1 rendered disease-free), adjuvant pembrolizumab for one year has shown an overall survival benefit in the KEYNOTE-564 trial and is discussed at post-surgical tumour boards in the NCR. If recurrence occurs, it is most commonly in the lung, followed by bone, liver and the surgical bed. Early detection of recurrence through structured surveillance allows timely intervention with systemic therapy or metastasectomy.

Q: How do I manage the financial burden of long-term immunotherapy?

Immunotherapy-based treatment for metastatic kidney cancer is expensive and often continues for up to two years or until disease progression. The total cost can exceed 30 to 50 lakh depending on the regimen. Practical steps include: asking your medical oncologist about pharmaceutical company patient assistance programmes (PAPs) for nivolumab or pembrolizumab, which can reduce or eliminate drug cost for eligible patients; checking PMJAY, CGHS, ECHS or state scheme eligibility for the surgical and radiation components to free up resources for drug costs; applying to Rashtriya Arogya Nidhi or PMNRF for one-time grants; contacting NGOs such as Indian Cancer Society or CanSupport for financial counselling; and discussing with your oncologist whether a regimen using more affordable generic TKIs (sunitinib or cabozantinib monotherapy) is a clinically reasonable alternative if immunotherapy is financially unsustainable. The decision to substitute a less expensive regimen should be made jointly with your treating physician based on your IMDC risk group and disease burden.

Sources: [^1]: Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs. Eur Urol. 2022;82(5):489-507. [^2]: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual, 8th ed. Springer; 2017. [^3]: Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model. Lancet Oncol. 2013;14(2):141-148. [^4]: Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400. [^5]: Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-1671. [^6]: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/kidrp.html. [^7]: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100E: Personal Habits and Indoor Combustions. Lyon: International Agency for Research on Cancer; 2012. [^8]: Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. [^9]: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 106: Trichloroethylene, Tetrachloroethylene, and Some Other Chlorinated Agents. Lyon: IARC; 2014. [^10]: Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-2067. [^11]: Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis. 2014;7:253-260. [^12]: Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2(2):157-164. [^13]: ICMR National Cancer Registry Programme. Three-Year Report of Population-Based Cancer Registries: 2012-2014. Bengaluru: National Centre for Disease Informatics and Research; 2016. [^14]: Indian Robotic Partial Nephrectomy Collaborative Group. Perioperative, functional, and oncological outcomes of robotic-assisted partial nephrectomy in 1,267 Indian patients: a multicentre analysis. (Published 2025, PubMed 40525006). [^15]: Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214): 5-year outcomes. N Engl J Med. 2021;384:829-839. [^16]: Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426): extended follow-up. J Clin Oncol. 2023;41(22):3789-3796. [^17]: Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma (CheckMate 9ER). N Engl J Med. 2021;384:829-841. [^18]: Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma (CLEAR). N Engl J Med. 2021;384:1289-1300. [^19]: Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (JAVELIN Renal 101). N Engl J Med. 2019;380:1103-1115. [^20]: Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma (METEOR). N Engl J Med. 2015;373:1814-1823. [^21]: Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma (Study 205). Lancet Oncol. 2015;16(15):1473-1482. [^22]: Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma (CheckMate 025). N Engl J Med. 2015;373:1803-1813. [^23]: Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS). Lancet. 2011;378(9807):1931-1939. [^24]: Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma (RECORD-1). Lancet. 2008;372(9637):449-456. [^25]: Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(3):305-312. [^26]: Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma (KEYNOTE-564). N Engl J Med. 2024;390:1359-1371. [^27]: Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA). N Engl J Med. 2018;379:417-427. [^28]: Bex A, Mulders P, Jewett M, et al. Immediate versus deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib (SURTIME). Eur Urol. 2019;76(1):78-87. [^29]: Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68(3):408-415. [^30]: Siva S, Louie AV, Warner A, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024;25(2):e75-e89. [^31]: Ravindranath L, Ramakrishnan S, Patel VG, et al. Cost-effectiveness of the first-line treatment options for metastatic renal cell carcinoma in India. JCO Glob Oncol. 2023;9:e2200246. [^32]: National Health Authority, Government of India. Ayushman Bharat PM-JAY Health Benefits Package 2.0. https://nha.gov.in. [^33]: NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 4.2024. National Comprehensive Cancer Network. [^34]: ESMO Clinical Practice Guidelines: Renal Cell Carcinoma. Ann Oncol. 2024;35(7):610-630. [^35]: Ravindranath L, et al. Cost analysis of first-line immunotherapy-TKI combinations versus sunitinib monotherapy in Indian mRCC patients: per-cycle and six-month cost projections. JCO Glob Oncol. 2023;9:e2200246. [^36]: Clinical Trials Registry of India. http://ctri.nic.in. [^37]: Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2 alpha in renal cell carcinoma with belzutifan: a multicentre, open-label, dose-escalation, phase 1b-2 trial (LITESPARK-004 long-term follow-up). Lancet Oncol. 2024. [^38]: Choueiri TK, Powles T, Albiges L, et al. Belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005). Lancet. 2024;403:1411-1421.